Epilepsy Talk
$112 billion new Alzheimer’s drug in question
July 13, 2021
4 Comments
4 Comments
Getting the FDA to retract a decision is like getting the toothpaste back in the tub, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all star Alzheimer’s drug aducanumab.
Posted in Epilepsy, Medication Issues, News, Research
Tags: $112 billion costs, &56000 a year, alzheimer's, FDA, Medicare, not proven, side effects
Tags: $112 billion costs, &56000 a year, alzheimer's, FDA, Medicare, not proven, side effects
Two Tests Could Aid in Risk Assessment and Early Diagnosis of Alzheimer’s
January 19, 2011
6 Comments
6 Comments
From “The New York Times”, published January 18, 2011…
“Researchers are reporting major advances toward resolving two underlying problems involving Alzheimer’s disease: How do you know if someone who is demented has it? And how can you screen the general population to see who is at risk?…”
Posted in Epilepsy, News, Research
Tags: alzheimer's, diagnosis, mental decline, predict, risks, tests
Tags: alzheimer's, diagnosis, mental decline, predict, risks, tests
About the author
Epilepsy Talk 